AOST2032 Supplemental Per Case Reimbursement (Feasibility Phase)

Medicine and Dentistry

1. Cabozantinib 100%
2. Osteosarcoma 83%
3. Chemotherapy 66%
4. Protein Tyrosine Kinase 50%
5. Tyrosine-Kinase Inhibitor 50%
6. Arm 33%
7. Diseases 33%
8. Event Free Survival 33%
9. Pelvic Tumor 16%
10. Wound Healing 16%
11. Primary Tumor 16%
12. Survival Rate 16%
13. Acute Myelogenous Leukemia 16%
14. Cancer 16%
15. Soft Tissue Sarcoma 16%
16. Metastatic Carcinoma 16%
17. Hepatocellular Carcinoma 16%
18. Cytotoxic Chemotherapy 16%
19. Prospective Study 16%
20. Cisplatin 16%
21. Doxorubicin 16%
22. Methotrexate 16%
23. Signal Transduction 16%
24. Adolescence 16%